PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and pCode coupling buffer sets… Read more
PlexBio Co., Ltd. (6572) - Total Assets
Latest total assets as of June 2025: NT$524.37 Million TWD
Based on the latest financial reports, PlexBio Co., Ltd. (6572) holds total assets worth NT$524.37 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PlexBio Co., Ltd. - Total Assets Trend (2020–2024)
This chart illustrates how PlexBio Co., Ltd.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PlexBio Co., Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
PlexBio Co., Ltd.'s total assets of NT$524.37 Million consist of 93.7% current assets and 6.3% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 46.6% |
| Accounts Receivable | NT$3.98 Million | 0.7% |
| Inventory | NT$37.30 Million | 6.5% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$433.00K | 0.1% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how PlexBio Co., Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PlexBio Co., Ltd.'s current assets represent 93.7% of total assets in 2024, unchanged from 93.7% in 2020.
- Cash Position: Cash and equivalents constituted 46.6% of total assets in 2024, up from 38.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 6.5% of total assets.
PlexBio Co., Ltd. Competitors by Total Assets
Key competitors of PlexBio Co., Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
PlexBio Co., Ltd. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PlexBio Co., Ltd. generates 0.22x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - PlexBio Co., Ltd. is currently not profitable relative to its asset base.
PlexBio Co., Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 4.03 | 8.26 |
| Quick Ratio | 2.58 | 3.77 | 7.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$318.64 Million | NT$ 423.52 Million | NT$ 338.97 Million |
PlexBio Co., Ltd. - Advanced Valuation Insights
This section examines the relationship between PlexBio Co., Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 10.8% |
| Total Assets | NT$572.38 Million |
| Market Capitalization | $8.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values PlexBio Co., Ltd.'s assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: PlexBio Co., Ltd.'s assets grew by 10.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for PlexBio Co., Ltd. (2020–2024)
The table below shows the annual total assets of PlexBio Co., Ltd. from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$572.38 Million | +10.78% |
| 2023-12-31 | NT$516.66 Million | -11.25% |
| 2022-12-31 | NT$582.15 Million | -20.56% |
| 2021-12-31 | NT$732.80 Million | -10.98% |
| 2020-12-31 | NT$823.23 Million | -- |